These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 10810778)

  • 21. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacoeconomics perspectives: payers, providers, and patients.
    Am J Manag Care; 1998 Apr; 4(4 Suppl):S221-4. PubMed ID: 10184937
    [No Abstract]   [Full Text] [Related]  

  • 23. Economic issues in coronary heart disease prevention.
    Reckless JP
    Curr Opin Lipidol; 1996 Dec; 7(6):356-62. PubMed ID: 9117138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Statins in the prevention of coronary heart disease.
    Williamson DR; Pharand C
    Pharmacotherapy; 1998; 18(2):242-54. PubMed ID: 9545143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.
    Coukell AJ; Wilde MI
    Pharmacoeconomics; 1998 Aug; 14(2):217-36. PubMed ID: 10186462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.
    Prosser LA; Stinnett AA; Goldman PA; Williams LW; Hunink MG; Goldman L; Weinstein MC
    Ann Intern Med; 2000 May; 132(10):769-79. PubMed ID: 10819699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis of treatments to reduce cholesterol levels, blood pressure and smoking for the prevention of coronary heart disease: evaluative study carried out in Spain.
    Plans-Rubió P
    Pharmacoeconomics; 1998 May; 13(5 Pt 2):623-43. PubMed ID: 17165328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Broader indication for treatment with statins; the 'heart protection study'].
    Stalenhoef AF; Stuyt PM
    Ned Tijdschr Geneeskd; 2002 Oct; 146(41):1921-3. PubMed ID: 12404905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical context: current concepts of coronary heart disease management.
    Jacobson TA
    Am J Med; 2001 Apr; 110 Suppl 6A():3S-11S. PubMed ID: 11311191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipid-lowering for prevention of coronary heart disease: what policy now?
    Ul Haq I; Ramsay LE; Pickin DM; Yeo WW; Jackson PR; Payne JN
    Clin Sci (Lond); 1996 Oct; 91(4):399-413. PubMed ID: 8983865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Rationing in German health care with particular consideration of oncology: view points of German stakeholders--a qualitative interview study].
    Lange J; Gönner C; Vollmann J; Rauprich O
    Gesundheitswesen; 2015 Jan; 77(1):8-15. PubMed ID: 24696371
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Therapy and prevention of coronary heart diseases through lowering of the serum cholesterol levels; third consensus 'Cholesterol'. Consensus Working Group, CBO].
    Simoons ML; Casparie AF
    Ned Tijdschr Geneeskd; 1998 Sep; 142(38):2096-101. PubMed ID: 9856223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: application to Germany, Spain and Norway.
    Cook JR; Yin D; Alemao E; Davies G; Krobot KJ; Veltri E; Lipka L; Badia X
    Pharmacoeconomics; 2004; 22 Suppl 3():49-61. PubMed ID: 15669153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic implications of lipid-lowering trials: current considerations in selecting a statin.
    Farmer JA
    Am J Cardiol; 1998 Sep; 82(6A):26M-31M. PubMed ID: 9766345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cholesterol reduction and coronary artery disease. An overview of clinical trials up to 1986.
    Tikkanen MJ; Pyörälä K
    Drugs; 1988; 36 Suppl 3():27-31. PubMed ID: 3076117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cost-effectiveness of atorvastatin for the prevention of coronary disease. An analysis of the ASCOT study].
    Szucs TD; Klose G; Düsing R
    Dtsch Med Wochenschr; 2004 Jun; 129(25-26):1420-4. PubMed ID: 15213873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.
    Athyros VG; Papageorgiou AA; Mercouris BR; Athyrou VV; Symeonidis AN; Basayannis EO; Demitriadis DS; Kontopoulos AG
    Curr Med Res Opin; 2002; 18(4):220-8. PubMed ID: 12201623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strategies for reducing coronary risk factors in primary care: which is most cost effective?
    Field K; Thorogood M; Silagy C; Normand C; O'Neill C; Muir J
    BMJ; 1995 Apr; 310(6987):1109-12. PubMed ID: 7742678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of statins.
    Huse DM; Russell MW; Miller JD; Kraemer DF; D'Agostino RB; Ellison RC; Hartz SC
    Am J Cardiol; 1998 Dec; 82(11):1357-63. PubMed ID: 9856919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improving health outcomes without increasing costs: maximizing the full potential of lipid reduction therapy in the primary and secondary prevention of coronary heart disease.
    Jacobson TA
    Curr Opin Lipidol; 1997 Dec; 8(6):369-74. PubMed ID: 9412778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.